NeuroSense Therapeutics Ltd. (NRSN) News
Follow NeuroSense Therapeutics Ltd. (NRSN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 11 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
NeuroSense Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Ratings actions from Benzinga
NEWS | Sep 28, 2026, 10:30 AM UTC
L
HC Wainwright & Co. maintains Buy rating on NeuroSense Therapeutics, $52 price target
HC Wainwright & Co. maintained their Buy rating on NeuroSense Therapeutics's stock with a price target of $52.00.The price target implies an upside of 648.2% from the Sep 25 close of $6.95.Key takeaways from the analyst
EQUITY | Sep 28, 2026, 10:20 AM UTC
L
NeuroSense Therapeutics 1H Loss/Shr $2.10 >NRSN
NeuroSense Therapeutics 1H Loss/Shr $2.10 >NRSN
NEWS | Sep 25, 2026, 08:31 PM UTC
L
NeuroSense Provides Business Update and Progress for the First Half of 2026
CAMBRIDGE, Mass., Sept. 25, 2026 // -- Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative
NEWS | Sep 25, 2026, 08:30 PM UTC
L
NeuroSense Therapeutics initiated at Buy by HC Wainwright
HC Wainwright & Co. initiated NeuroSense Therapeutics at Buy, per Benzinga ratings actions.
EQUITY | Sep 03, 2026, 10:29 AM UTC
L
NeuroSense Therapeutics Q2'26 EPS seen at (0.20) USD
NeuroSense Therapeutics Ltd. is set to announce Q2'26 results on September 02. The Q2'26 revenue estimate is 0 USD, with EPS anticipated at (0.20) USD.
EARNINGS | Sep 01, 2026, 11:00 AM UTC
L
NeuroSense (NRSN) issues CEO letter to shareholders
NeuroSense (NRSN) has issued a CEO letter to shareholders, according to TradeXchange Newsdesk, with no additional figures or details provided in the alert.
EQUITY | Aug 13, 2026, 01:31 PM UTC
M
NeuroSense Advances Toward December 2026 Filing
NeuroSense completes pre-filing process with Health Canada
EQUITY | Aug 06, 2026, 03:29 PM UTC
L
NRSN Buy, $3 PT – funding remains the gating factor @ Roth
NRSN Buy, $3 PT – funding remains the gating factor @ Roth
EQUITY | Jul 23, 2026, 01:10 PM UTC
L
NRSN Neurosense Therapeutics - expects to file submission to health Canada in coming months
NRSN Neurosense Therapeutics - expects to file submission to health Canada in coming months
EQUITY | Jul 22, 2026, 12:35 PM UTC
H
NRSN Reports Positive Biomarker Findings
NeuroSense reports positive biomarker findings from Phase 2 RoAD proof-of-concept study of PrimeC in Alzheimer's disease
EQUITY | Jun 25, 2026, 01:23 PM UTC